Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Molecular Profile | BTK T474I |
Therapy | NX-2127 |
Indication/Tumor Type | diffuse large B-cell lymphoma |
Response Type | sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
BTK T474I | diffuse large B-cell lymphoma | sensitive | NX-2127 | Preclinical - Cell culture | Actionable | In a preclinical study, NX-2127 inhibited viability of a diffuse large B-cell lymphoma cell line expressing BTK T474I in culture (PMID: 38301010). | 38301010 |
PubMed Id | Reference Title | Details |
---|---|---|
(38301010) | Kinase-impaired BTK mutations are susceptible to clinical-stage BTK and IKZF1/3 degrader NX-2127. | Full reference... |